Corteva Tidigare resultatutveckling
Tidigare kriterier kontrolleras 0/6
Corteva s intäkter har minskat med en genomsnittlig årlig takt på -8.1%, medan Chemicals -branschen såg intäkter på sjunkande på 2.9% årligen. Intäkterna har varit växande med en genomsnittlig takt på 2.1% per år. Corteva s avkastning på eget kapital är 4.3% och den har en nettomarginal på 6.1%.
Viktig information
-8.14%
Tillväxttakt i vinsten
-5.94%
Tillväxttakt för EPS
| Chemicals Tillväxt i branschen | 12.93% |
| Intäkternas tillväxttakt | 2.15% |
| Avkastning på eget kapital | 4.32% |
| Nettomarginal | 6.09% |
| Senaste uppdateringen av resultatet | 30 Jun 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Uppdatering av berättelse • Aug 04
CTVA: Upcoming Seed Spinoff And Crop Protection Pipeline Will Reshape Earnings Mix
Analysts lifted their price target for Corteva to $92.40 from $90.05, pointing to updated expectations around the Vylor seed spinoff, the crop protection and fertilizer backdrop, and the revised P/E and profitability assumptions cited in recent research. Analyst Commentary Recent research on Corteva centers on how the Vylor seed spinoff, crop protection trends, and fertilizer market conditions may affect valuation, growth prospects, and execution risk.Seeking Alpha • Jul 31
Corteva: Strong Fundamentals, Limited Upside
Summary Corteva, Inc. stands as a global leader in pure agri-tech, emphasizing R&D for advanced seed genetics and sustainable crop solutions. My prior Hold ratings on CTVA underestimated the market's preference for quality, execution, and improved business visibility over strict valuation metrics. CTVA has significantly outperformed the broader market by four times and its ETF peers by more than two times since my earlier reviews. The investment thesis now centers on CTVA's superior execution and enhanced operational visibility as key drivers of its recent outperformance. Read the full article on Seeking AlphaAnalysartikel • Jun 20
Corteva (CTVA) Stock Could Be 13% Undervalued After FMC Herbicide Deal
Why the new FMC partnership matters for Corteva stock Corteva (CTVA) recently signed a multi-year, co-exclusive supply and license agreement with FMC Corporation for rimisoxafen herbicide technology, giving the company another tool in corn and soybean crop protection. The deal covers North and South American markets, includes a US$200 million prepurchase payment from Corteva, and allows both companies to create their own premix formulations. Commercial sales are targeted by the end of the...Uppdatering av berättelse • Jun 14
CTVA: Upcoming Spin Focused On Seed And Crop Protection Will Reshape Earnings Mix
Corteva's updated analyst price target edges higher by about $0.14 to roughly $90.05, as analysts refine their assumptions around revenue growth, profit margins and future P/E in light of recent target increases across the Street for the upcoming spin focused on seed and crop protection businesses. Analyst Commentary Recent research updates around Corteva cluster around the upcoming spin of its seed and crop protection businesses, with a series of higher price targets reflecting refreshed views on growth, execution and valuation for what some refer to as "New Corteva." Bullish analysts point to recalibrated assumptions on revenue, margins and P/E, while more cautious voices focus on whether the standalone company can consistently deliver against those expectations once separated.Uppdatering av berättelse • May 31
CTVA: SpinCo Separation And Biofungicide Collaboration Will Reshape Future Earnings Mix
The analyst price target for Corteva is updated to $89.90 from $86.05 as analysts note that the market is treating "New Corteva" like a no-growth commodity chemical company. They instead highlight expectations for a healthier standalone growth profile, modestly higher profit margins, and a slightly lower assumed future P/E multiple.Analysartikel • May 14
Corteva's (NYSE:CTVA) Performance Is Even Better Than Its Earnings Suggest
Even though Corteva, Inc.'s ( NYSE:CTVA ) recent earnings release was robust, the market didn't seem to notice...Uppdatering av berättelse • Apr 27
CTVA: Fair Value View Weighs Crop Protection Uncertainty And Planned SpinCo Separation
Corteva's analyst price target has increased by about $2, as analysts cite updated earnings models, a revised fair value of $86.05, a slightly adjusted discount rate, and modest changes to revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Street research on Corteva has been active, with several price target revisions and a mix of ratings changes that give you both supportive and cautious signals to weigh.Uppdatering av berättelse • Apr 13
CTVA: Fair Value View Balances Crop Protection Risks And Upcoming SpinCo Separation
The analyst price target for Corteva has moved modestly higher to align with a fair value estimate of about $84, as analysts factor in updated earnings models, slightly adjusted revenue growth and profit margin assumptions, and recent price target changes across several firms. Analyst Commentary Recent Street research on Corteva shows a mix of higher price targets and a few rating downgrades, so you are seeing both optimism and caution reflected in the current analyst debate.Uppdatering av berättelse • Mar 28
CTVA: Crop Protection Uncertainty And SpinCo Separation Will Shape Future Risk Balance
The analyst price target for Corteva has been nudged higher, with a modest fair value uplift to $83.95 as analysts balance a series of recent target increases from multiple firms against more cautious views tied to softer crop protection trends. Analyst Commentary Recent research on Corteva reflects a split view, with several firms lifting price targets while others turn more cautious on near term fundamentals, especially in crop protection.Uppdatering av berättelse • Mar 12
CTVA: Mixed Crop Protection Outlook And New SpinCo Plan Will Shape Risk Balance
The analyst price target for Corteva edges higher to $83.33 from $82.76, as analysts factor in slightly firmer long term revenue growth and profit margins, while balancing more cautious views on crop protection trends and a modestly lower discount rate. Analyst Commentary Recent research on Corteva reflects a split view, with several firms lifting price targets while others turn more cautious on execution in crop protection.Uppdatering av berättelse • Feb 26
CTVA: Sector Uncertainty And New Ventures Will Shape Forward Risk Balance
Corteva's analyst fair value estimate has edged up to $82.76 from $82.05 as analysts refine their models and price targets following recent earnings updates and a broad wave of upward target revisions across the Street. Analyst Commentary Recent Street research around Corteva reflects an active debate, with several firms adjusting price targets and a mix of upgrades and downgrades around the latest earnings update.Uppdatering av berättelse • Feb 11
CTVA: Mixed Sector Backdrop And New Ventures Will Shape Future Prospects
Corteva's analyst fair value estimate has increased to $82.05 from $78.43 as analysts factor in slightly stronger revenue growth assumptions, a higher future P/E multiple, and a modestly lower discount rate, even as projected profit margins are trimmed. Analyst Commentary Recent Street research on Corteva is mixed, with several bullish analysts lifting price targets while a few high profile firms turn more cautious.Uppdatering av berättelse • Jan 26
CTVA: Seed And Crop Protection Split Will Shape Balanced Future Prospects
Narrative Update Analysts have modestly raised their price expectations for Corteva, with the updated fair value estimate moving by about US$0.48 per share. This reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E, and is supported by recent target increases from several firms.Uppdatering av berättelse • Jan 11
CTVA: Planned Seed And Pesticide Split Will Support Future Earnings Power
Analysts lifted their blended fair value estimate for Corteva by about $0.19 to roughly $77.95 per share, reflecting updated price targets that factor in a mixed backdrop for chemicals and agriculture but continued confidence in the company’s ability to increase earnings. Analyst Commentary Recent research on Corteva reflects a mix of optimism and caution, with price targets clustered in the mid to high US$70s and one outlier in the low US$80s.Uppdatering av berättelse • Dec 18
CTVA: Planned Seed And Pesticide Split Will Unlock Future Earnings Power
The analyst price target for Corteva has been nudged higher by approximately $0.05 to about $77.76, as analysts factor in a slightly lower discount rate and modestly improved long term growth expectations, despite broadly cautious sector commentary and recent target reductions. Analyst Commentary Street research on Corteva reflects a divided but generally constructive view, with price targets drifting lower but ratings remaining skewed toward positive as investors reassess the company’s post breakup trajectory and near term earnings backdrop.Uppdatering av berättelse • Dec 03
CTVA: Planned Seed And Pesticide Split Will Unlock Future Earnings Power
Our analyst price target for Corteva has been trimmed modestly in line with recent Street moves, as analysts factor in lower sector multiples and near term earnings uncertainty around the planned split, while still recognizing the company’s intact innovation engine and long term earnings growth potential. Analyst Commentary Street views on Corteva have become more bifurcated following the announced split, with valuation targets reset lower but ratings broadly supportive of the long term strategic rationale and earnings power.Analysartikel • Nov 26
A Look At The Fair Value Of Corteva, Inc. (NYSE:CTVA)
Key Insights Corteva's estimated fair value is US$63.85 based on 2 Stage Free Cash Flow to Equity Current share price...Uppdatering av berättelse • Nov 19
CTVA: Upcoming Seed And Pesticide Split Will Unlock Shareholder Value
The analyst consensus price target for Corteva has been modestly reduced, slipping from approximately $77.86 to $77.71. Analysts reflect more cautious expectations for earnings growth in light of a mixed agricultural outlook and anticipated impacts from the company's planned business split.Uppdatering av berättelse • Nov 05
CTVA: Share Split Will Drive Shareholder Value Unlocking Amid Ongoing Business Realignment
Analysts have modestly reduced their average price target for Corteva by approximately $1.20. They cite a more cautious outlook amid challenging crop protection conditions and the company's recent announcement to split into two separate businesses.Uppdatering av berättelse • Oct 22
Analysts Offer Mixed Views as Corteva Eyes Split and Updates Guidance Amid Modest Valuation Shift
Analysts have modestly reduced their price target for Corteva by about $0.76 to $79.05. They cite uncertainty regarding the company’s planned split and the retention of legacy liabilities, though fundamentals and growth remain largely stable.Uppdatering av berättelse • Oct 08
High-Yield Seed Demand And Eco Policies Will Transform Agriculture
Corteva's analyst price target has been modestly reduced by $0.95 per share. Analysts cite continued uncertainty around the planned corporate split and complex crop protection market dynamics.Uppdatering av berättelse • Sep 04
High-Yield Seed Demand And Eco Policies Will Transform Agriculture
Analysts maintained their price target for Corteva at $80.76, citing margin expansion and EBITDA growth driven by successful innovation, favorable market fundamentals, and strong execution. Analyst Commentary Ongoing cost reductions, successful innovation, and strong execution are driving margin expansion and double-digit EBITDA growth.Seeking Alpha • Apr 21
Corteva: Upgraded To Strong Buy On Tariffs, Currency Tailwinds, Strong Guidance
Summary Upgrading Corteva from Buy to Strong Buy due to macro conditions, including tariff-induced supply shocks, rising commodity prices, and currency tailwinds. Corteva's diversified supply chain and local production in seeds position it to benefit from regionalization and potential inflationary pressures in the agricultural sector. Strong Q4 earnings, record operating EBITDA margin, and robust free cash flow support the bullish outlook, with significant shareholder returns through dividends and buybacks. Improved valuation at 20x forward earnings, solid balance sheet, and technical indicators suggest potential for further upside in the current market environment. Read the full article on Seeking AlphaSeeking Alpha • Mar 30
Pure Market Inefficiency In Corteva Preferreds Pricings
Summary This article explores a market inefficiency in fixed-income securities, specifically between Corteva's $4.50 and $3.50 Series Cumulative Preferred Stocks. We identified an arbitrage opportunity due to technical buying, making it an ideal pair trade with identical issues from the same company. On 02/09/2025, we recommended CTA-B for our investment-grade long-duration portfolio. On 02/10/2025, technical high-volume buying in CTA-A turned our initial investment idea into a pair trade. This pair trade highlights how technical factors can create profitable opportunities in fixed-income securities, especially among identical issues from the same issuer. Read the full article on Seeking AlphaFördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur Corteva tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 30 Jun 26 | 17,812 | 1,085 | 3,623 | 1,493 |
| 31 Mar 26 | 17,889 | 1,252 | 3,628 | 1,480 |
| 31 Dec 25 | 17,401 | 1,193 | 3,515 | 1,474 |
| 30 Sep 25 | 17,469 | 1,681 | 3,420 | 1,426 |
| 30 Jun 25 | 17,177 | 1,469 | 3,397 | 1,423 |
| 31 Mar 25 | 16,833 | 1,142 | 3,325 | 1,405 |
| 31 Dec 24 | 16,908 | 851 | 3,340 | 1,402 |
| 30 Sep 24 | 16,637 | 670 | 3,333 | 1,394 |
| 30 Jun 24 | 16,901 | 874 | 3,325 | 1,381 |
| 31 Mar 24 | 16,834 | 698 | 3,318 | 1,353 |
| 31 Dec 23 | 17,226 | 929 | 3,295 | 1,337 |
| 30 Sep 23 | 17,344 | 1,119 | 3,303 | 1,320 |
| 30 Jun 23 | 17,531 | 1,112 | 3,238 | 1,297 |
| 31 Mar 23 | 17,738 | 1,234 | 3,099 | 1,264 |
| 31 Dec 22 | 17,455 | 1,205 | 3,010 | 1,216 |
| 30 Sep 22 | 17,109 | 1,401 | 2,706 | 1,192 |
| 30 Jun 22 | 16,703 | 1,760 | 2,417 | 1,177 |
| 31 Mar 22 | 16,078 | 1,776 | 2,143 | 1,174 |
| 31 Dec 21 | 15,655 | 1,812 | 1,891 | 1,187 |
| 30 Sep 21 | 15,383 | 1,756 | 2,055 | 1,176 |
| 30 Jun 21 | 14,875 | 1,330 | 2,213 | 1,163 |
| 31 Mar 21 | 14,439 | 1,075 | 2,417 | 1,143 |
| 31 Dec 20 | 14,217 | 736 | 2,675 | 1,142 |
| 30 Sep 20 | 13,993 | 594 | 2,744 | 1,127 |
| 30 Jun 20 | 14,041 | 470 | 2,839 | 1,132 |
| 31 Mar 20 | 14,406 | 179 | 2,856 | 1,128 |
| 31 Dec 19 | 13,846 | -288 | 2,874 | 1,147 |
| 30 Sep 19 | 13,678 | -1,322 | 2,797 | 1,202 |
| 30 Jun 19 | 13,714 | -6,453 | 2,764 | 1,238 |
| 31 Mar 19 | 12,921 | -6,965 | 2,662 | 1,312 |
| 31 Dec 18 | 14,287 | -6,813 | 2,766 | 1,355 |
| 30 Sep 18 | 14,299 | -3,538 | 2,786 | 1,393 |
| 30 Jun 18 | 14,220 | 1,261 | 2,888 | 1,455 |
| 31 Mar 18 | 14,230 | 1,898 | 2,930 | 1,482 |
| 31 Dec 17 | 10,684 | 2,081 | 3,082 | 1,075 |
| 31 Dec 16 | 14,041 | 503 | 2,937 | 1,507 |
Kvalitetsintäkter: CTVA har en stor engång förlust av $1.1B {1 månader till 30th June, 2026 1 månader) 30th June, 2026.
Växande vinstmarginal: CTVA s nuvarande netto vinstmarginaler (6.1%) är lägre än förra året (8.6%).
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: CTVA s intäkter har minskat med 8.1% per år under de senaste 5 åren.
Accelererande tillväxt: CTVA s har haft negativ intäktstillväxt under det senaste året, så det kan inte jämföras med dess 5-åriga genomsnitt.
Resultat vs industri: CTVA hade negativ intäktstillväxt ( -26.1% ) under det senaste året, vilket gör det svårt att jämföra med branschens genomsnitt Chemicals ( 2.4% ).
Avkastning på eget kapital
Hög ROE: CTVA s avkastning på eget kapital ( 4.3% ) anses vara låg.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/13 01:55 |
| Aktiekurs vid dagens slut | 2026/09/11 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Corteva, Inc. bevakas av 34 analytiker. 20 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| null null | Argus Research Company |
| Benjamin Theurer | Barclays |
| Aron Ceccarelli | Berenberg |